The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.
The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.
The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.
NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...
NEW YORK – Precision oncology firm Cleveland Diagnostics announced Monday that its IsoPSA test for prostate cancer has received approval from the US Food and Drug Administration. The blood-based test ...
Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback